Judith Butler on the Violence of Neglect Amid a Health Crisis
By Francis Wade,
The Nation
| 05. 13. 2020
A conversation with the theorist about her new book, The Force of Nonviolence, and the need for global solidarity in the pandemic world
Image via Wikimedia Commons
Judith Butler has achieved a status that few other living academics have acquired: For each published work that she issues, reams of discussion and critique are produced in response, so much so that they have engendered microdisciplines in the many fields in which she is an expert: gender, politics, literary studies, and more. Her argument for gender as performative, which first gained attention through her 1990 book Gender Trouble, established her as a leading gender theorist before subsequent works directed greater focus toward the exercise of state power via, among others, rhetoric and violence.
In the wake of the 9/11 attacks, Butler began working on a series of essays, later collected into Precarious Life: The Powers of Mourning and Violence(2004), in which she elaborated her thesis on “grievability.” She argued that the loss of certain communities—generally First World, white, middle class, heterosexual—produces a national mourning that is recognized and amplified—in obituary pages, news channels, and public commemoration services. Others seen as weak or different (such as people with AIDS in the US and the...
Related Articles
By Vittoria Vardanega, SWI swissinfo.ch | 02.13.2026
In recent years, sperm donation has produced family trees of unprecedented size, stretching across countries and, in some cases, continents. Stories of “mass donors” have captured public attention, most recently through the Netflix documentary series, The Man with 1,000 Kids...
By Jonathan D. Moreno, Hastings Center Bioethics Forum | 02.09.2026
When I began to write a book about bioethics and the rules-based international order, the idea that the world was facing the greatest geopolitical change since World War II was uncontroversial for those who were paying attention to such esoterica...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...